ABSTRACT
References 495
It is unfortunate that 24 years after initial descriptions of the therapeutic benefits of tacrine (Summers et al., 1986) we still only have symptomatic therapies for Alzheimer’s disease (AD) and no therapies for the other dementias. Only four drugs are regularly used for AD (donepezil, galantamine, rivastigmine and memantine) and no new drug has been marketed for almost 15 years. We desperately need disease-modifying therapies as well as new symptomatic therapies for AD.
